Your browser doesn't support javascript.
loading
Increased Myosin light chain 9 expression during Kawasaki disease vasculitis.
Kobayashi, Hironobu; Kimura, Motoko Y; Hasegawa, Ichita; Suganuma, Eisuke; Ikehara, Yuzuru; Azuma, Kazuhiko; Ito, Toshihiro; Ebata, Ryota; Kurashima, Yosuke; Kawasaki, Yohei; Shiko, Yuki; Saito, Naoki; Iwase, Hirotaro; Lee, Youngho; Noval Rivas, Magali; Arditi, Moshe; Zuka, Masahiko; Hamada, Hiromichi; Nakayama, Toshinori.
Afiliación
  • Kobayashi H; Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Kimura MY; Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Hasegawa I; Department of Experimental Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Suganuma E; Department of Experimental Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Ikehara Y; Chiba University "Synergy Institute for Futuristic Mucosal Vaccine Research and Development (cSIMVa), Japan Initiative for World-leading Vaccine Research and Development Centers, Japan Agency for Medical Research and Development (AMED), Chiba, Japan, Chiba, Japan.
  • Azuma K; Department of Experimental Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Ito T; Division of Infectious Diseases and Immunology, Allergy, Saitama Children's Medical Center, Saitama, Japan.
  • Ebata R; Department of Molecular and Tumor Pathology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Kurashima Y; Department of Molecular and Tumor Pathology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Kawasaki Y; Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Shiko Y; Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Saito N; Department of Innovative Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Iwase H; Clinical Research Center, Chiba University Hospital, Chiba, Japan.
  • Lee Y; Clinical Research Center, Chiba University Hospital, Chiba, Japan.
  • Noval Rivas M; Department of Legal Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Arditi M; Department of Legal Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Zuka M; Department of Pediatrics, Division of Infectious Diseases and Immunology, Guerin Children's at Cedars-Sinai Medical Center, Los Angeles, CA, United States.
  • Hamada H; Infectious and Immunologic Diseases Research Center (IIDRC) and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
  • Nakayama T; Department of Pediatrics, Division of Infectious Diseases and Immunology, Guerin Children's at Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Front Immunol ; 13: 1036672, 2022.
Article en En | MEDLINE | ID: mdl-36685558
Introduction: Kawasaki disease (KD) is an acute systemic vasculitis that predominantly afflicts children. KD development is known to be associated with an aberrant immune response and abnormal platelet activation, however its etiology is still largely unknown. Myosin light chain 9 (Myl9) is known to regulate cellular contractility of both non-muscle and smooth muscle cells, and can be released from platelets, whereas any relations of Myl9 expression to KD vasculitis have not been examined. Methods: Plasma Myl9 concentrations in KD patients and children with febrile illness were measured and associated with KD clinical course and prognosis. Myl9 release from platelets in KD patients was also evaluated in vitro. Myl9 expression was determined in coronary arteries from Lactobacillus casei cell wall extract (LCWE)-injected mice that develop experimental KD vasculitis, as well as in cardiac tissues obtained at autopsy from KD patients. Results and discussion: Plasma Myl9 levels were significantly higher in KD patients during the acute phase compared with healthy controls or patients with other febrile illnesses, declined following IVIG therapy in IVIG-responders but not in non-responders. In vitro, platelets from KD patients released Myl9 independently of thrombin stimulation. In the LCWE-injected mice, Myl9 was detected in cardiac tissue at an early stage before inflammatory cell infiltration was observed. In tissues obtained at autopsy from KD patients, the highest Myl9 expression was observed in thrombi during the acute phase and in the intima and adventitia of coronary arteries during the chronic phase. Thus, our studies show that Myl9 expression is significantly increased during KD vasculitis and that Myl9 levels may be a useful biomarker to estimate inflammation and IVIG responsiveness to KD.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Vasculitis / Síndrome Mucocutáneo Linfonodular Límite: Animals Idioma: En Revista: Front Immunol Año: 2022 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Vasculitis / Síndrome Mucocutáneo Linfonodular Límite: Animals Idioma: En Revista: Front Immunol Año: 2022 Tipo del documento: Article País de afiliación: Japón